The Institute for Translational Medicine and Therapeutics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
Aliment Pharmacol Ther. 2021 Feb;53(4):510-518. doi: 10.1111/apt.16206. Epub 2020 Dec 5.
Coeliac disease arises in genetically susceptible individuals, in particular in carriers of HLA-DQ2/DQ8 risk alleles and is associated with various comorbidities. Coeliac disease may confer an increased mortality, but the data are conflicting.
We aimed to characterize mortality and morbidity in patients with coeliac disease with a special focus on the role of the number of HLA risk alleles.
We studied coeliac disease-associated morbidity and mortality in ~500 000 participants of the UK Biobank including 2482 individuals with the diagnosis of coeliac disease. We used an unbiased, multivariable Phenome-Wide Association Study (PheWAS) method to uncover the coeliac disease-associated disorders. The tag SNP approach was used to divide the coeliac disease subjects into HLA-DQ2/DQ8-based risk categories.
We found 225 ICD-10 codes significantly associated with coeliac disease. During the median follow-up of 10.7 years, coeliac disease individuals (n = 2482) had higher overall mortality (HR 1.6 [95% CI, 1.4-1.8]) than controls and both an increased occurrence of and an increased mortality from cancer, respiratory and cardiovascular diseases (HR 1.4-1.6). Coeliac disease individuals with 2 HLA-DQ2/8 risk alleles had a similar overall mortality as coeliac disease participants with 0-1 HLA-DQ2/8 alleles, but were more likely to die from lymphoproliferative diseases (HR 7.6 [95% CI, 1.01-57.25]).
Our data suggest that the increased mortality from lymphoproliferative diseases is restricted to those coeliac patients with 2 HLADQ2/8 alleles and that a combination of coeliac disease and HLADQ2/8 alleles is needed to increase the susceptibility. Once confirmed, closer monitoring may be warranted in this high-risk subpopulation.
乳糜泻是一种在遗传易感个体中发生的疾病,特别是在携带 HLA-DQ2/DQ8 风险等位基因的个体中,并与各种合并症相关。乳糜泻可能会增加死亡率,但数据存在争议。
我们旨在描述乳糜泻患者的死亡率和发病率,特别关注 HLA 风险等位基因数量的作用。
我们研究了英国生物库中约 500000 名参与者的乳糜泻相关发病率和死亡率,其中包括 2482 名乳糜泻患者。我们使用无偏的多变量表型全基因组关联研究(PheWAS)方法来发现乳糜泻相关疾病。使用标签 SNP 方法将乳糜泻患者分为基于 HLA-DQ2/DQ8 的风险类别。
我们发现 225 个 ICD-10 代码与乳糜泻显著相关。在中位随访 10.7 年期间,乳糜泻患者(n=2482)的总死亡率更高(HR 1.6 [95%CI,1.4-1.8]),癌症、呼吸和心血管疾病的发生率和死亡率均增加(HR 1.4-1.6)。携带 2 个 HLA-DQ2/8 风险等位基因的乳糜泻患者的总体死亡率与携带 0-1 个 HLA-DQ2/8 等位基因的乳糜泻患者相似,但更有可能死于淋巴增生性疾病(HR 7.6 [95%CI,1.01-57.25])。
我们的数据表明,淋巴增生性疾病的死亡率增加仅限于携带 2 个 HLA-DQ2/8 等位基因的乳糜泻患者,并且需要乳糜泻和 HLA-DQ2/8 等位基因的组合来增加易感性。一旦得到证实,在这个高风险亚群中可能需要更密切的监测。